Literature DB >> 25670826

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.

Ali Asmar1, Lene Simonsen2, Meena Asmar2, Sten Madsbad3, Jens J Holst4, Erik Frandsen5, Cedric Moro6, Thomas Jonassen7, Jens Bülow8.   

Abstract

The present experiments were performed to elucidate the acute effects of intravenous infusion of glucagon-like peptide (GLP)-1 on central and renal hemodynamics in healthy men. Seven healthy middle-aged men were examined on two different occasions in random order. During a 3-h infusion of either GLP-1 (1.5 pmol·kg⁻¹·min⁻¹) or saline, cardiac output was estimated noninvasively, and intraarterial blood pressure and heart rate were measured continuously. Renal plasma flow, glomerular filtration rate, and uptake/release of hormones and ions were measured by Fick's Principle after catheterization of a renal vein. Subjects remained supine during the experiments. During GLP-1 infusion, both systolic blood pressure and arterial pulse pressure increased by 5±1 mmHg (P=0.015 and P=0.002, respectively). Heart rate increased by 5±1 beats/min (P=0.005), and cardiac output increased by 18% (P=0.016). Renal plasma flow and glomerular filtration rate as well as the clearance of Na⁺ and Li⁺ were not affected by GLP-1. However, plasma renin activity decreased (P=0.037), whereas plasma levels of atrial natriuretic peptide were unaffected. Renal extraction of intact GLP-1 was 43% (P<0.001), whereas 60% of the primary metabolite GLP-1 9-36amide was extracted (P=0.017). In humans, an acute intravenous administration of GLP-1 leads to increased cardiac output due to a simultaneous increase in stroke volume and heart rate, whereas no effect on renal hemodynamics could be demonstrated despite significant extraction of both the intact hormone and its primary metabolite.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  blood pressure; cardiac output; glucagon-like peptide-1; heart rate; renal plasma flow

Mesh:

Substances:

Year:  2015        PMID: 25670826     DOI: 10.1152/ajpendo.00429.2014

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  19 in total

Review 1.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

2.  Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.

Authors:  Laurence G Trahair; Michael Horowitz; Julie E Stevens; Christine Feinle-Bisset; Scott Standfield; Diana Piscitelli; Christopher K Rayner; Adam M Deane; Karen L Jones
Journal:  Diabetologia       Date:  2015-06-06       Impact factor: 10.122

3.  Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

Authors:  Mark M Smits; Marcel H A Muskiet; Lennart Tonneijck; Trynke Hoekstra; Mark H H Kramer; Michaela Diamant; Daniël H van Raalte
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

4.  Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.

Authors:  Marcel H A Muskiet; Lennart Tonneijck; Mark M Smits; Mark H H Kramer; D Margriet Ouwens; Bolette Hartmann; Jens J Holst; A H Jan Danser; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2021-10-06       Impact factor: 6.408

5.  Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors.

Authors:  Jonas Ronn; Elisa P Jensen; Nicolai J Wewer Albrechtsen; Jens Juul Holst; Charlotte M Sorensen
Journal:  Physiol Rep       Date:  2017-12

6.  Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.

Authors:  Lasse Bremholm; Ulrik B Andersen; Mads Hornum; Linda Hilsted; Simon Veedfald; Bolette Hartmann; Jens Juul Holst
Journal:  Physiol Rep       Date:  2017-02

7.  Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.

Authors:  Ali Asmar; Meena Asmar; Lene Simonsen; Sten Madsbad; Jens J Holst; Bolette Hartmann; Charlotte M Sorensen; Jens Bülow
Journal:  Physiol Rep       Date:  2017-02

8.  Cardiorenal Involvement in Metabolic Syndrome Induced by Cola Drinking in Rats: Proinflammatory Cytokines and Impaired Antioxidative Protection.

Authors:  Matilde Otero-Losada; Hernán Gómez Llambí; Graciela Ottaviano; Gabriel Cao; Angélica Müller; Francisco Azzato; Giuseppe Ambrosio; José Milei
Journal:  Mediators Inflamm       Date:  2016-05-31       Impact factor: 4.711

9.  Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.

Authors:  Lennart Tonneijck; Mark M Smits; Marcel H A Muskiet; Trynke Hoekstra; Mark H H Kramer; A H Jan Danser; Michaela Diamant; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetologia       Date:  2016-04-01       Impact factor: 10.122

10.  Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree.

Authors:  Katrine Dahl Bjørnholm; Maria Elm Ougaard; Gry Freja Skovsted; Lotte Bjerre Knudsen; Charles Pyke
Journal:  Endocrinol Diabetes Metab       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.